Chinese Pharma Simcere Files IND For Humanized Rabbit Monoclonal Antibody
This article was originally published in PharmAsia News
Executive SummaryHONG KONG - Chinese drug manufacturer and distributor Simcere Pharmaceutical Group filed an investigational new drug application earlier this month with China's State FDA to launch a Phase I trial of APX003, a novel humanized rabbit monoclonal antibody to treat solid-tumor cancer
You may also be interested in...
The Domain Associates/Rusnano tie-up looks new on the surface, but is driven by a familiar imperative – the need to find new funding streams for biotechs still working to build up their exit value.